Moleculin's Annamycin Shows No Cardiotoxicity in ASCO 2026 Data — Moleculin Biotech, Inc.

Event summary

Moleculin presented ASCO 2026 data showing no detectable cardiotoxicity with Annamycin despite cumulative exposure levels exceeding conventional anthracycline limits.
Pooled analysis of 90 patients across five clinical trials demonstrated no statistically significant change in left ventricular ejection fraction (LVEF).
Independent review by Cleveland Clinic cardiology specialists validated the cardiac safety findings.
Annamycin's Phase 2b/3 MIRACLE trial for relapsed/refractory AML is on track for initial patient data unblinding in June 2026.

The big picture

Moleculin's data challenges the historical trade-off between efficacy and cardiotoxicity in anthracycline-based chemotherapy, potentially expanding treatment options for relapsed/refractory AML patients. The findings come at a critical juncture as the company advances its pivotal Phase 2b/3 trial, with external validation from Cleveland Clinic adding credibility to its differentiated safety profile.

What we're watching

Clinical Validation: Whether the cardiac safety profile of Annamycin can be confirmed in larger studies and sustain regulatory approval pathways.
Trial Execution: The pace at which Moleculin can unblind and report initial patient data from the Phase 2b/3 MIRACLE trial.
Market Differentiation: How Annamycin's potential to avoid cardiotoxicity will position it against existing anthracycline therapies in the oncology market.